Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Elafibranor

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 240,860Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 923978-27-2, Gft505, Gft-505, 824932-88-9, Elafibranor [inn], Elafibranor [usan]
    Molecular Formula
    C22H24O4S
    Molecular Weight
    384.5  g/mol
    InChI Key
    AFLFKFHDSCQHOL-IZZDOVSWSA-N
    FDA UNII
    2J3H5C81A5
    Elafibranor (code name GFT505) is a multimodal and pluripotent medication for treatment of atherogenic dyslipidemia for an overweight patient with or without diabetes. It is an oral treatment that acts on the 3 sub-types of PPAR (PPARa, PPARg, PPARd) with a preferential action on PPARa. As of February 2016, elafibranor has completed 8 clinical trials and a phase III is in progress.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    2-[2,6-dimethyl-4-[(E)-3-(4-methylsulfanylphenyl)-3-oxoprop-1-enyl]phenoxy]-2-methylpropanoic acid
    2.1.2 InChI
    InChI=1S/C22H24O4S/c1-14-12-16(13-15(2)20(14)26-22(3,4)21(24)25)6-11-19(23)17-7-9-18(27-5)10-8-17/h6-13H,1-5H3,(H,24,25)/b11-6+
    2.1.3 InChI Key
    AFLFKFHDSCQHOL-IZZDOVSWSA-N
    2.1.4 Canonical SMILES
    CC1=CC(=CC(=C1OC(C)(C)C(=O)O)C)C=CC(=O)C2=CC=C(C=C2)SC
    2.1.5 Isomeric SMILES
    CC1=CC(=CC(=C1OC(C)(C)C(=O)O)C)/C=C/C(=O)C2=CC=C(C=C2)SC
    2.2 Other Identifiers
    2.2.1 UNII
    2J3H5C81A5
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propenyl)phenoxyl)-2-methylpropanoic Acid

    2. Gft505

    2.3.2 Depositor-Supplied Synonyms

    1. 923978-27-2

    2. Gft505

    3. Gft-505

    4. 824932-88-9

    5. Elafibranor [inn]

    6. Elafibranor [usan]

    7. Gft 505

    8. Elafibranor(gft505)

    9. 2-[2,6-dimethyl-4-[(e)-3-(4-methylsulfanylphenyl)-3-oxoprop-1-enyl]phenoxy]-2-methylpropanoic Acid

    10. 2j3h5c81a5

    11. Elafibranor (usan)

    12. (e)-2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxoprop-1-en-1-yl)phenoxy)-2-methylpropanoic Acid

    13. 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxoprop-1-en-1-yl)phenoxy)-2-methylpropanoic Acid

    14. 2-{2,6-dimethyl-4-[(1e)-3-[4-(methylsulfanyl)phenyl]-3-oxoprop-1-en-1-yl]phenoxy}-2-methylpropanoic Acid

    15. Propanoic Acid, 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxo-1-propen-1-yl)phenoxy)-2-methyl-

    16. Unii-2j3h5c81a5

    17. Gft-505;elafibranor

    18. Surecn815512

    19. Elafibranor [who-dd]

    20. Schembl815512

    21. Chembl3707395

    22. Schembl16552997

    23. Gtpl11135

    24. Ex-a757

    25. Dtxsid601045330

    26. Bcp19067

    27. Zhb93288

    28. Bdbm50502541

    29. Mfcd27987940

    30. S3720

    31. Zinc114643710

    32. Ccg-268462

    33. Cs-5522

    34. Db05187

    35. (e)-2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxoprop-1-enyl)phenoxy)-2-methylpropanoic Acid

    36. Ac-31455

    37. Ac-35189

    38. As-57112

    39. Be163306

    40. Hy-16737

    41. D11208

    42. A856857

    43. J-690356

    44. Q15409440

    45. 2-(2,6-dimethyl-4-(3-(4-(methylsulfanyl)phenyl)-3-oxoprop- 1-en-1-yl)phenoxy)-2-methylpropanoic Acid

    46. 2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxoprop-1-en-1-yl)phenoxy)-2-methylpropanoicacid

    47. 2-[2,6-dimethyl-4-[(1e)-3-[4-(methylthio)phenyl]-3-oxo-1-propen-1-yl]phenoxy]-2-methylpropanoic Acid

    48. Propanoic Acid, 2-(2,6-dimethyl-4-((1e)-3-(4-(methylthio)phenyl)-3-oxo-1-propen-1-yl)phenoxy)-

    49. Propanoic Acid, 2-[2,6-dimethyl-4-[(1e)-3-[4-(methylthio)phenyl]-3-oxo-1-propen-1-yl]phenoxy]-2-methyl-

    2.4 Create Date
    2006-10-25
    3 Chemical and Physical Properties
    Molecular Weight 384.5 g/mol
    Molecular Formula C22H24O4S
    XLogP35.1
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count5
    Rotatable Bond Count7
    Exact Mass384.13953042 g/mol
    Monoisotopic Mass384.13953042 g/mol
    Topological Polar Surface Area88.9 Ų
    Heavy Atom Count27
    Formal Charge0
    Complexity537
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count1
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Investigated for use/treatment in atherosclerosis and diabetes mellitus type 2.

    Treatment of primary biliary cholangitis

    Treatment of non-alcoholic fatty liver disease (NAFLD) including non-alcoholic steatohepatitis (NASH)

    5 Pharmacology and Biochemistry
    5.1 Mechanism of Action

    GFT505 is an oral treatment that acts on the 3 sub-types of PPAR (PPARa, PPARg, PPARd) with a preferential action on PPARa. It has a sophisticated mechanism of action. It is able to differentially recruit cofactors to the nuclear receptor, which subsequently lead to differential regulation of genes and biological effect. Therefore, the ability to identify and profile the activity of selective nuclear receptor modulator (SNuRMs) is a powerful approach to select innovative drug candidates with improved efficacy and diminished side effects. These pluripotent and multimodal molecules have significant positive effects on obesity, insulin-resistance and diabetes, atherosclerosis, inflammation, and the lipid triad (increasing of HDL cholesterol, lowering of triglycerides and LDL cholesterol).